Comparative Pharmacology
Head-to-head clinical analysis: CHOLINE C 11 versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLINE C 11 versus XENOVIEW.
CHOLINE C-11 vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choline C-11 is a radioactive diagnostic agent; after intravenous administration, it is taken up by cells and phosphorylated by choline kinase. It accumulates in tissues with high choline metabolism, such as tumors (e.g., prostate cancer), allowing positron emission tomography (PET) imaging. The mechanism for tumor uptake is related to increased cell membrane synthesis and choline kinase activity.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
Intravenous: 370-740 MBq (10-20 mCi) as a single injection for PET imaging. Dose depends on patient weight, camera sensitivity, and imaging protocol.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
The terminal elimination half-life of [11C]choline in plasma is approximately 5-10 minutes. This short half-life is consistent with its use as a PET imaging agent, allowing same-day imaging without significant residual radiation exposure.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal excretion; approximately 70-80% of administered radioactivity is eliminated in urine within 2 hours, with less than 5% fecal elimination.
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical